Skip header and navigation
Did you mean markets?

Narrow By

176 records – page 1 of 9.

Atlas of Thyroid and Neuroendocrine Tumor Markers

https://libcat.nshealth.ca/en/permalink/provcat43325
Luca Giovanella, editor. --Cham: Springer , c2018.
Available Online
View e-Book
Location
Online
This book highlights the increase in thyroid tumors and NET and demonstrates the growing importance of circulating markers in diagnosis as well as treatment and follow-up. Dramatic technical improvements have heightened the clinical impact of well-established, conventional biochemical markers. In addition, more recent genetic and molecular approaches have provided innovative molecular markers. In this context, effective communication between clinicians and laboratory physicians/scientists is es…
Available Online
View e-Book
Other Authors
Giovanella, Luca
Responsibility
Luca Giovanella, editor
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xii, 249 p.) : 41 illus., 30 illus. in color
ISBN
9783319625065
9783319625058 (print ed.)
9783319625072 (print ed.)
9783319873305 (print ed.)
Subjects (MeSH)
Biomarkers, Tumor
Neuroendocrine Tumors - diagnosis
Neuroendocrine Tumors - therapy
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - therapy
Specialty
Endocrinology
Medical Oncology
Abstract
This book highlights the increase in thyroid tumors and NET and demonstrates the growing importance of circulating markers in diagnosis as well as treatment and follow-up. Dramatic technical improvements have heightened the clinical impact of well-established, conventional biochemical markers. In addition, more recent genetic and molecular approaches have provided innovative molecular markers. In this context, effective communication between clinicians and laboratory physicians/scientists is essential in allowing all those involved to fully profit from these exciting advances. In this comprehensive, up-to-date book, authors from different laboratory and clinical areas link laboratory and clinical topics. Analytical problems such as interferences, false-negative and false-positive results are discussed in depth, and flow-charts offer insights into identifying and avoiding them. Illustrated clinical cases detail the clinical role and limitations of different tumor markers. Lastly, it explores health technology assessment and economic issues. This is a valuable resource for endocrinologists, oncologists, nuclear medicine physicians, scientists and technologists who want to keep abreast of the latest developments.
Contents
Part I. Pathology and Pathobiology -- 1. Pathology and Immunohistochemistry in Thyroid Tumors -- 2. Pathology of Neuroendocrine Neoplasms: Morphological, Immunophenotypical, and Circulating Molecular Markers -- 3. Circulating Biomarkers: Biological Basis, Methods, and Interpretation Criteria -- Part II. Differentiated Thyroid Cancer -- 4. Differentiated Thyroid Cancer: Diagnosis, Therapy, and Follow-Up -- 5. Thyroglobulin and Thyroglobulin Antibodies -- 6. Circulating Molecular Biomarkers in Thyroid Cancer -- 7. Circulating Epithelial Tumor Cells in Thyroid Carcinoma -- Part III. Medullary Thyroid Carcinoma -- 8. Medullary Thyroid Carcinoma (MTC): Diagnosis, Treatment and Follow-Up -- 9. Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma -- 10. Procalcitonin: Are We Ready for Clinical Use? -- Part IV. Aggressive and Rare Thyroid Carcinoma -- 11. Aggressive Variants of Thyroid Carcinoma -- 12. Circulating Mucins and Cytokeratins in Aggressive Thyroid Cancers -- Part V. Thyroid Biomarkers on Fine-Needle Washouts -- 13. Measurement of Thyroid Tumor Markers on Fine-Needle Washouts -- Part VI. Neuroendocrine Tumors -- 14. Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up -- 15. Circulating Markers in Neuroendocrine Tumors -- 16. Neuroendocrine Gene Transcripts: The Role of Molecular Biomarkers in Diagnosis and Management.
Format
e-Book
Publication Type
Atlas
Location
Online
Less detail

Biomarkers of kidney disease

https://libcat.nshealth.ca/en/permalink/provcat31569
edited by Charles L. Edelstein. (2nd ed.) --Amsterdam, Netherlands: Elsevier , c2017.
Available Online
View e-Book
Access
Registration required for PDF access.
Location
Online
Available Online
View e-Book
Other Authors
Edelstein, Charles L
Responsibility
edited by Charles L. Edelstein
Edition
2nd ed.
Place of Publication
Amsterdam, Netherlands
Publisher
Elsevier
Date of Publication
c2017
Physical Description
1 online resource
ISBN
9780128030141
Subjects (MeSH)
Kidney Diseases - diagnosis
Biological Markers
Subjects (LCSH)
Kidney Diseases - diagnosis
Biological Markers
Kidneys - Diseases - Molecular diagnosis
Biochemical markers
Access
Registration required for PDF access.
Format
e-Book
Location
Online
Less detail

Biomarkers of kidney disease

https://libcat.nshealth.ca/en/permalink/provcat50417
Edelstein, Charles. (2nd ed.) --Philadelphia, PA: Elsevier , 2017.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Edelstein, Charles
Edition
2nd ed.
Place of Publication
Philadelphia, PA
Publisher
Elsevier
Date of Publication
2017
ISBN
9780128030141
Subjects (MeSH)
Kidney Diseases - diagnosis
Biological Markers
Notes
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Format
e-Book
Location
Online
Less detail

Cardiovascular Biomarkers : Pathophysiology and Disease Management

https://libcat.nshealth.ca/en/permalink/provcat30100
edited by David A. Morrow. --Totowa, NJ: Humana Press , c2006.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Morrow, David A
Responsibility
edited by David A. Morrow
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2006
Series Title
Contemporary cardiology (Totowa, N.J. : Unnumbered)
ISBN
9781597450515
Subjects (MeSH)
Biological Markers
Heart Diseases - therapy
Subjects (LCSH)
Cardiology
Biochemistry
Physiology
Format
e-Book
Location
Online
Less detail

Bladder Tumors : Molecular Aspects and Clinical Management

https://libcat.nshealth.ca/en/permalink/provcat30059
edited by Vinata B. Lokeshwar, Axel S. Merseburger, Stefan H. Hautmann. --Totowa, NJ: Springer Science+Business Media , c2011.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Lokeshwar, Vinata B
Other Authors
Merseburger, Axel S
Hautmann, Stefan H
Responsibility
edited by Vinata B. Lokeshwar, Axel S. Merseburger, Stefan H. Hautmann
Place of Publication
Totowa, NJ
Publisher
Springer Science+Business Media
Date of Publication
c2011
Series Title
Cancer drug discovery and development
ISBN
9781607619284
Subjects (MeSH)
Tumor Markers, Biological
Urinary Bladder Neoplasms
Subjects (LCSH)
Oncology
Urology
Format
e-Book
Location
Online
Less detail

Natriuretic Peptides : The Hormones of the Heart

https://libcat.nshealth.ca/en/permalink/provcat28235
edited by Aldo Clerico, Michele Emdin. --Milan: Springer-Verlag Italia , c2006.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Clerico, Aldo
Other Authors
Emdin, Michele
Responsibility
edited by Aldo Clerico, Michele Emdin
Place of Publication
Milan
Publisher
Springer-Verlag Italia
Date of Publication
c2006
ISBN
9788847004986
Subjects (MeSH)
Biological Markers
Cardiovascular Diseases - physiopathology
Natriuretic Peptides - analysis
Subjects (LCSH)
Cardiology
Endocrinology 
Format
e-Book
Location
Online
Less detail

Principles of Molecular Oncology

https://libcat.nshealth.ca/en/permalink/provcat30037
edited by Miguel H. Bronchud, Mary Ann Foote, Giuseppe Giaccone, Olufunmilayo Olopade, Paul Workman. (3rd ed.) --Totowa, NJ: Humana Press , c2008.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Bronchud, Miguel H
Other Authors
Foote, Mary Ann
Giaccone, Giuseppe
Olopade, Olufunmilayo
Workman, Paul
Responsibility
edited by Miguel H. Bronchud, Mary Ann Foote, Giuseppe Giaccone, Olufunmilayo Olopade, Paul Workman
Edition
3rd ed.
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2008
ISBN
9781597454704
Subjects (MeSH)
Molecular Diagnostic Techniques
Neoplasms - therapy
Tumor Markers, Biological
Subjects (LCSH)
Oncology
Hematology
Format
e-Book
Location
Online
Less detail

Neurodegenerative diseases : clinical aspects, molecular genetics and biomarkers

https://libcat.nshealth.ca/en/permalink/provcat33732
Daniela Galimberti, Elio Scarpini, editors. --London: Springer , c2014.
Available Online
View e-Book
Location
Online
This book gives an overview of the current knowledge on the most common neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and additional neurodegenerative diseases. Different aspects of each disease are reviewed, including clinical issues, treatments, basic discoveries (genetics and molecular biology), and translation of basic research into biomarkers for early diagnosis. In addition, emerging data indicate that neurodeg…
Available Online
View e-Book
Other Authors
Galimberti, Daniela
Scarpini, E
Responsibility
Daniela Galimberti, Elio Scarpini, editors
Place of Publication
London
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xix, 253 pages)
ISBN
9781447163800 (electronic bk.)
9781447163794
Subjects (MeSH)
Alzheimer Disease
Neurodegenerative Diseases
Biological Markers
Subjects (LCSH)
Nervous system - Degeneration
Neurology
Neurosciences
Abstract
This book gives an overview of the current knowledge on the most common neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and additional neurodegenerative diseases. Different aspects of each disease are reviewed, including clinical issues, treatments, basic discoveries (genetics and molecular biology), and translation of basic research into biomarkers for early diagnosis. In addition, emerging data indicate that neurodegeneration seems to also be present in classically non-degenerative disorders. Therefore, a chapter about overlapping mechanisms between dementias and psychiatric disorders is included, as well as a description of the role of neurodegeneration in multiple sclerosis. Neurodegenerative Diseases is aimed at clinicians, particularly those working in academic hospitals. This multidisciplinary book will also be of interest to basic researchers in medical fields.
Contents
Genetics and Epigenetics: Basic Concepts -- Alzheimer's Disease: Clinical Aspects and Treatments -- Autosomal Dominant Alzheimer's Disease: Underlying Causes -- Genetic Risk Factors for Alzheimer's Disease -- The Role of Cerebrovascular Disease in Cognitive Decline -- Nongenetic Risk Factors for Alzheimer's Disease -- Nongenetic Risk Factors for Alzheimer's Disease -- Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes -- Alzheimer's Disease and Frontotemporal Lobar Degeneration: Mouse Models -- Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia -- Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration: Imaging -- Amyotrophic Lateral Sclerosis: Genotypes and Phenotypes -- Uncommon Dementias -- Neurodevelopment Alterations, Neurodegeneration, and Immunoinflammatory Patterns in the Pathophysiology of Schizophrenia -- Neurodegeneration and Multiple Sclerosis.
Format
e-Book
Location
Online
Less detail

Biotargets of Cancer in Current Clinical Practice

https://libcat.nshealth.ca/en/permalink/provcat31016
Mauro Bologna, editor. --New York, NY: Humana Press , c2012.
Available Online
View e-Book
Location
Online
Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (in…
Available Online
View e-Book
Other Authors
Bologna, Mauro
Responsibility
Mauro Bologna, editor
Place of Publication
New York, NY
Publisher
Humana Press
Date of Publication
c2012
Physical Description
1 online resource (xvi, 563 p. : 100 ill., 57 ill. in color)
Series Title
Current clinical pathology
ISBN
9781617796159
Subjects (MeSH)
Biological Markers
Molecular Targeted Therapy
Neoplasms - therapy
Subjects (LCSH)
Medical laboratories
Oncology
Pathology
Abstract
Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.
Contents
Central Nervous System Tumors -- Head and Neck Tumors -- Thyroid Cancer -- Targeted Therapies for Non-Small Cell Lung Cancer -- Non-Hodgkin Lymphomas -- Leukemias -- Breast Cancer -- Esophago-Gastric Cancer -- Colorectal Cancer -- Hepatocellular Carcinoma -- Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma -- Bladder Cancer -- Biomarkers in Prostate cancer -- Ovarian Cancer -- Uterine Cancer: The Influence of Genetics and Environment on Cell Cycling Pathways in Cancer -- Biotargets in Sarcomas: The Past, Present and a Look into the Future -- Melanoma and other skin cancers -- Molecular pathology of cancer metastasis: suggestions for future therapy -- Current and future developments in cancer therapy research: miRNAs as new promising targets or tools.
Format
e-Book
Location
Online
Less detail

Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer : New Molecular Aspects and their Potential as Targets

https://libcat.nshealth.ca/en/permalink/provcat28069
edited by Stephen Hiscox, Julia Gee, Robert I. Nicholson. --[Dordrecht]: Springer Netherlands , c2009.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Hiscox, Stephen
Other Authors
Gee, Julia
Nicholson, Robert I
Responsibility
edited by Stephen Hiscox, Julia Gee, Robert I. Nicholson
Place of Publication
[Dordrecht]
Publisher
Springer Netherlands
Date of Publication
c2009
ISBN
9781402085260
Subjects (MeSH)
Breast Neoplasms
Drug Resistance, Neoplasm
Tumor Markers, Biological
Subjects (LCSH)
Oncology
Gynecology
Endocrinology 
Pharmacy
Format
e-Book
Location
Online
Less detail

Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

https://libcat.nshealth.ca/en/permalink/provcat30996
Michael J. Murphy, editor. --New York, NY: Springer , c2012.
Available Online
View e-Book
Location
Online
This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target …
Available Online
View e-Book
Other Authors
Murphy, Michael J
Responsibility
Michael J. Murphy, editor
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xiv, 322 p. : 29 ill., 24 ill. in color)
Series Title
Current clinical pathology
ISBN
9781607614333
Subjects (MeSH)
Drug Delivery Systems
Drug Design
Melanoma - diagnosis
Melanoma - therapy
Tumor Markers, Biological
Subjects (LCSH)
Dermatology
Oncology
Pathology
Abstract
This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.
Contents
Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma -- Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play -- Molecular Pathogenesis of Melanoma: Established and Novel Pathways -- Staging of Melanoma -- Clinical and Histopathological Parameters in Melanoma -- Genetic/Epigenetic Biomarkers: Distinction of Melanoma from Other Melanocytic Neoplasms -- mRNA Biomarkers in Melanoma -- Epigenetic Biomarkers in Melanoma -- microRNA Biomarkers in Melanoma -- MicroRNAs as Biomarkers and Therapeutic Targets in Melanoma -- Mitochondrial DNA Biomarkers in Melanoma -- Tissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (A) Diagnosis -- Tissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (B) Prognostication -- Tissue-Based Protein Biomarkers in Melanoma: Mass Spectrometry-Based Strategies -- Serological Biomarkers in Melanoma -- Molecular Markers of Lymph Node Disease in Melanoma -- Melanoma Cell Propagation: Cancer Stem Cell, Clonal Evolution and Interconversion Models of Tumorigenicity -- Surgical Management of Melanoma: Concept of Field Cancerization and Molecular Evaluation of Tissue Margins -- Chemotherapy for Melanoma -- Molecular-Targeted Therapy for Melanoma -- Anti-Angiogenesis Therapy for Melanoma -- Immunological Biomarkers and Immunotherapy for Melanoma -- Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview.
Format
e-Book
Location
Online
Less detail

Color Atlas of Immunocytochemistry in Diagnostic Cytology

https://libcat.nshealth.ca/en/permalink/provcat30417
edited by Parvin Ganjei-Azar, Mehrdad Nadji. --Boston, MA: Springer Science+Business Media , c2007.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Ganjei-Azar, Parvin
Other Authors
Nadji, Mehrdad
Responsibility
edited by Parvin Ganjei-Azar, Mehrdad Nadji
Place of Publication
Boston, MA
Publisher
Springer Science+Business Media
Date of Publication
c2007
ISBN
9780387321226
Subjects (MeSH)
Cytodiagnosis - Atlases
Immunohistochemistry - methods - Atlases
Neoplasms - diagnosis - Atlases
Neoplasms - metabolism
Tumor Markers, Biological
Subjects (LCSH)
Cytology
Immunology
Pathology
Format
e-Book
Location
Online
Less detail

Cancer immunotherapy meets oncology : in honor of Christoph Huber

https://libcat.nshealth.ca/en/permalink/provcat33730
Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee, editors. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical developmen…
Available Online
View e-Book
Other Authors
Britten, Cedrik Michael
Huber, Christoph
Responsibility
Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee, editors
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (ix, 248 pages)
ISBN
9783319051048 (electronic bk.)
9783319051031
Subjects (MeSH)
Immunotherapy
Neoplasms - immunology
Neoplasms - therapy
Tumor Markers, Biological
Subjects (LCSH)
Cancer - Immunotherapy
Oncology
Cancer Research
Pharmacology/Toxicology
Immunology
Abstract
This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Contents
Part I. Immunological and Regulatory Framework for Immuno-oncology -- From Basic Immunology to New Therapies for Cancer Patients -- How T Cells Single Out Tumor Cells: "And That Has Made All the Difference" -- Effects of Regulatory T Cell-Dendritic Cell Interactions on Adaptive Immune Responses -- Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Cancer Vaccines -- Immunoguiding, the Final Frontier in the Immunotherapy of Cancer -- Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress -- Part II. Immunotherapies -- Reflections on Cancer Vaccines -- Dendritic Cell-Based Cancer Vaccines -- mRNA Vaccination and Personalized Cancer Therapy -- Antibody Therapy in Oncology -- Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation -- The ABCs of T Cell Receptor Gene Therapy -- The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic -- Part III. Cancer Entities -- Immunotherapy of Malignant Melanoma -- Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF -- Recent Developments in the Active Immunotherapy of Renal Cell Cancer -- Current Status of Immunotherapy in Gastroesophageal Cancer -- Non-small Cell Lung Cancer, NSCLC -- Towards More Specificity and Effectivity in the Antileukemia Immune Response -- Part IV. Biomarkers -- Molecular and Metabolic Cues of the Key-Lock Paradigm Dictating Immunogenic Cell Death -- Pathogenesis of Minimal Residual Disease: CTCs as Novel Biomarkers in Cancer Disease -- Genomics Meets Cancer Immunotherapy -- Part V. Featured Chapters -- Oncolytic Viruses -- Part VI. Final Remarks -- Final Words.
Format
e-Book
Location
Online
Less detail

Prevention of Bone Metastases

https://libcat.nshealth.ca/en/permalink/provcat31127
Markus Joerger, Michael Gnant, editors. --Berlin, Heidelberg: Springer , c2012.
Available Online
View e-Book
Location
Online
Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with br…
Available Online
View e-Book
Other Authors
Joerger, Markus
Gnant, Michael
Responsibility
Markus Joerger, Michael Gnant, editors
Place of Publication
Berlin, Heidelberg
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (ix, 233 p. : 23 ill., 13 ill. in color)
Series Vol.
192
Series Title
Recent results in cancer research
ISBN
9783642218927
Subjects (MeSH)
Biological Markers
Bone Neoplasms - prevention & control
Bone Neoplasms - secondary
Cytostatic Agents - therapeutic use
Diphosphonates - therapeutic use
Subjects (LCSH)
Oncology
Abstract
Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab.
Contents
Preclinical Models that Illuminate the Bone Metastasis Cascade -- The Role of Bone Microenvironment, Vitamin D and Calcium -- Bisphosphonates: Prevention of Bone Metastases in Breast Cancer -- Bisphosphonates: Prevention of Bone Metastases in Lung Cancer -- Bisphosphonates: Prevention of Bone Metastases in Prostate Cancer -- Targeting Bone in Myeloma -- Combinations of Bisphosphonates and Classical Anticancer Drugs: A Preclinical Perspective -- Perspectives in the Elderly Patient: Benefits and Limits of Bisphosphonates and Denosumab -- Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases -- Diagnostic and Prognostic Use of Bone Turnover Markers -- Osteolytic and Osteoblastic Bone Metastases: Two Extremes of the Same Spectrum?
Format
e-Book
Location
Online
Less detail

Molecular testing in cancer

https://libcat.nshealth.ca/en/permalink/provcat33595
George M. Yousef, Serge Jothy, editors. --New York: Springer , c2014.
Available Online
View e-Book
Location
Online
Molecular Testing in Cancer provides a state of the art review of clinically relevant molecular pathology in cancer. The book provides a brief, easy to read review of commonly employed diagnostic molecular techniques including recently developed "next generation" analytic tools, and offers a system-based run-through of the utility of molecular testing in individual cancer types, as well as reviewing current markers in cancer diagnosis, prognosis, and management. The volume also provides a prosp…
Available Online
View e-Book
Other Authors
Yousef, George M
Jothy, Serge
Responsibility
George M. Yousef, Serge Jothy, editors
Place of Publication
New York
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xi, 442 pages)
ISBN
9781489980502 (electronic bk.)
9781489980496
Subjects (MeSH)
Molecular Diagnostic Techniques
Neoplasms - diagnosis
Neoplasms - genetics
Tumor Markers, Biological
Subjects (LCSH)
Cancer - Molecular diagnosis
Pathology
Laboratory Medicine
Cancer Research
Abstract
Molecular Testing in Cancer provides a state of the art review of clinically relevant molecular pathology in cancer. The book provides a brief, easy to read review of commonly employed diagnostic molecular techniques including recently developed "next generation" analytic tools, and offers a system-based run-through of the utility of molecular testing in individual cancer types, as well as reviewing current markers in cancer diagnosis, prognosis, and management. The volume also provides a prospective for the future which includes recently characterized and emerging biomarkers.
Contents
Part I. Molecular Approaches and Techniques -- Transitioning Diagnostic Molecular Pathology to the Genomic Era: Cancer Somatic Mutation Panel Testing -- Conventional and Molecular Cytogenetics in Cancer -- Comparative Genomic Hybridization and Array Based CGH in Cancer -- Polymerase Chain Reaction -- Single Nucleotide Polymorphisms (SNPs) -- Clinical Application of DNA Sequencing: Sanger and Next-Generation Platforms -- Microarray-Based Investigations in Cancer -- Proteomics in Cancer Diagnostics -- Circulating Tumor Cells: A Noninvasive Liquid Biopsy in Cancer -- Molecular Applications in Various Malignancies -- Part II. Molecular Applications in Various Malignancies -- Molecular Testing in Hematologic Malignancies -- Molecular Testing in Breast Cancer -- Molecular Pathology of Gastrointestinal Tumors -- Molecular Testing in Pulmonary Tumors -- Molecular testing in Gynecological Malignancies -- Molecular Testing in CNS Tumors -- Molecular Testing in Adult Kidney Tumors -- Molecular Testing in Prostate Cancer -- Molecular Testing in Urothelial Tumors -- Molecular Testing in Thyroid Cancer -- Molecular Testing of Head and Neck Tumors -- Molecular Testing in Bone and Soft Tissue Tumors -- Molecular testing in Cutaneous Melanoma -- Molecular Testing in Paediatric Tumours -- Pharmacogenomics in Molecular Oncology -- Quality Assurance in Molecular Testing of Cancer.
Format
e-Book
Location
Online
Less detail

Caveolins in Cancer Pathogenesis, Prevention and Therapy

https://libcat.nshealth.ca/en/permalink/provcat30929
Isabelle Mercier, Jean-François Jasmin, Michael P. Lisanti, editors. --New York, NY: Springer , c2012.
Available Online
View e-Book
Location
Online
For more than a decade, caveolin proteins have attracted a lot of attention in the field of cancer research. Additional roles besides maintaining the structural integrity of caveolae (meaning "little caves" in latin) have been attributed to these complex proteins. In fact, they have emerged as important regulators of cell signaling, proliferation, invasion and angiogenesis. The current book focuses on caveolin-1, the best-studied and well- characterized of all three caveolin family members (cav…
Available Online
View e-Book
Other Authors
Mercier, Isabelle
Jasmin, Jean-François
Lisanti, Michael P
Responsibility
Isabelle Mercier, Jean-François Jasmin, Michael P. Lisanti, editors
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xi, 123 p. : 12 ill., 11 ill. in color)
Series Title
Current cancer research
ISBN
9781461410010
Subjects (MeSH)
Caveolae - pathology
Caveolin 1 - metabolism
Caveolin 1 - physiology
Neoplasms - metabolism
Signal transduction
Tumor Markers, Biological - metabolism
Subjects (LCSH)
Oncology
Biochemistry
Abstract
For more than a decade, caveolin proteins have attracted a lot of attention in the field of cancer research. Additional roles besides maintaining the structural integrity of caveolae (meaning "little caves" in latin) have been attributed to these complex proteins. In fact, they have emerged as important regulators of cell signaling, proliferation, invasion and angiogenesis. The current book focuses on caveolin-1, the best-studied and well- characterized of all three caveolin family members (caveolin-1, -2 and -3). As such, the current chapters illustrate the roles of caveolin-1 in breast, prostate, skin, colon, brain and pancreatic cancers, and highlight its specific contribution to tumor growth through epithelial and stromal interactions, as well as its involvement in angiogenesis. This book summarizes the existing literature and provides interesting new perspectives on future advancement and therapeutic possibilities involving caveolins in cancer. This work brings together highly respected and experienced scientists in the field of caveolins who wrote informative chapters on the role of caveolin-1 in cancer in a format that conveys its role as both a tumor suppressor and tumor promoter. We invite you to read, enjoy and be part of these new promising discoveries that are rapidly advancing the field of cancer research.
Contents
Preface -- Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression -- Caveolin-1 in Colon Cancer: the Flexible Connection to Wnt Signaling -- Caveolin-1 and Pancreatic Ductal Adenocarcinoma -- Caveolin-1 in Brain Tumors -- The Role of Caveolin-1 in Skin Cancer -- Caveolins and Tumor Angiogenesis -- Caveolin-1 and Breast Cancer -- Caveolin-1 and Cancer-Associated Stromal Fibroblasts -- Index.
Format
e-Book
Location
Online
Less detail

Molecular diagnostics and treatment of pancreatic cancer : systems and network biology approaches

https://libcat.nshealth.ca/en/permalink/provcat33143
edited by Asfar S. Azmi. --Amsterdam, Netherlands: Elsevier/AP , 2014.
Available Online
View e-Book
Access
Registration required for PDF access.
Location
Online
Molecular Diagnostics and Treatment of Pancreatic Cancer describes the different emerging applications of systems biology and how it is shaping modern pancreatic cancer research. This book begins by introducing the current state of the art knowledge, trends in diagnostics, progress in disease model systems as well as new treatment and palliative care strategies in pancreatic cancer. Specific sections are dedicated to enlighten the readers to newer discoveries that have emerged from gene expres…
Available Online
View e-Book
Other Authors
Azmi, Asfar S
Responsibility
edited by Asfar S. Azmi
Place of Publication
Amsterdam, Netherlands
Publisher
Elsevier/AP
Date of Publication
2014
Physical Description
1 online resource (xx, 446 p.)
ISBN
9781306642347 (electronic bk)
Subjects (MeSH)
Pancreatic Neoplasms - diagnosis
Molecular Diagnostic Techniques
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - therapy
Signal transduction
Tumor Markers, Biological
Subjects (LCSH)
Pancreas - Cancer - Molecular diagnosis
Pancreas - Cancer - Treatment
Pancreatic Neoplasms - diagnosis
Molecular Diagnostic Techniques
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - therapy
Signal Transduction
Tumor Markers, Biological
Abstract
Molecular Diagnostics and Treatment of Pancreatic Cancer describes the different emerging applications of systems biology and how it is shaping modern pancreatic cancer research. This book begins by introducing the current state of the art knowledge, trends in diagnostics, progress in disease model systems as well as new treatment and palliative care strategies in pancreatic cancer. Specific sections are dedicated to enlighten the readers to newer discoveries that have emerged from gene expression profiling, proteomics, metabolomics and systems level analyses of pancreatic cancer datasets.
Contents
Front Cover; MOLECULAR DIAGNOSTICS AND TREATMENT OF PANCREATIC CANCER: SYSTEMS AND NETWORK BIOLOGY APPROACHES; Copyright; DEDICATION; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; Section I -- Current Trends and Advances in Pancreatic Cancer; Chapter 1 -- Epidemiology, Treatment, and Outcome of Pancreatic Cancer; INTRODUCTION; EPIDEMIOLOGY AND ETIOLOGY OF PANCREATIC CANCER; TYPES OF PANCREATIC CANCER; CLINICAL PRESENTATION OF PANCREATIC CANCER; DIAGNOSIS OF PANCREATIC CANCER; TREATMENT OF PANCREATIC CANCER; POTENTIALLY CURATIVE SURGICAL TREATMENT; ADJUVANT AND NEOADJUVANT TREATMENT -- PROGNOSIS OF PANCREATIC CANCEROUTLOOK; REFERENCES; Chapter 2 -- Advances in Primary Cell Culture of Pancreatic Cancer; INTRODUCTION; CELL CULTURE OF PDAC; ISOLATION AND ESTABLISHMENT PROCEDURE; CHARACTERIZATION OF CELL CULTURES; MORPHOLOGY; GENOTYPING; PHENOTYPING; SECOND LEVEL OF BIOLOGICAL MODELS; THREE-DIMENSIONAL CELL CULTURES; IN VIVO MODELS; APPLICATIONS; CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; Chapter 3 -- Multimodal Therapies for Pancreatic Cancer; INTRODUCTION; CONCLUSION; REFERENCES; Chapter 4 -- The Role of Notch Signaling Pathway in the Progression of Pancreatic Cancer; INTRODUCTION -- NOTCH SIGNALING PATHWAYTHE ROLE OF NOTCH IN PC; NOTCH INHIBITION IS A NOVEL STRATEGY FOR PC TREATMENT; UNDERSTANDING NOTCH SIGNALING THROUGH SYSTEMS BIOLOGY; CONCLUSION; REFERENCES; Section II -- Gene Expression Profiling and Bioinformatics Analysis in Pancreatic Cancer; Chapter 5 -- Bioinformatics Analysis of Pancreas Cancer Genome in High-Throughput Genomic Technologies; INTRODUCTION; HETEROGENEITY AND QUALITY OF SAMPLES FOR HIGH-THROUGHPUT GENOMIC TECHNOLOGIES; MICROARRAYS; NEXT-GENERATION SEQUENCING; DATABASES AND RESOURCES; CONCLUSION AND FUTURE PERSPECTIVES; ACKNOWLEDGEMENTS; REFERENCES -- Chapter 6 -- Statistical Analysis of High-Dimensional Data for Pancreatic CancerINTRODUCTION; LASSO PENALIZED COX REGRESSION; DOUBLY REGULARIZED COX REGRESSION; PANCREATIC CANCER SURVIVAL ANALYSIS; ACKNOWLEDGMENTS; REFERENCES; Chapter 7 -- Gene Expression Profiling in Pancreatic Cancer; INTRODUCTION; SUMMARY; REFERENCES; Chapter 8 -- Genetic Susceptibility and Risk of Pancreatic Cancer; INTRODUCTION; FAMILIAL RISK OF PANCREATIC CANCER; RARE, HIGH-RISK PANCREATIC CANCER SUSCEPTIBILITY GENES AND MULTICANCER SYNDROMES; COMMON, LOW-RISK PANCREATIC CANCER SUSCEPTIBILITY LOCI -- COMMON PANCREATIC CANCER RISK LOCI IN NON-EUROPEAN POPULATIONSPATHWAY ANALYSES OF PANCREATIC CANCER GWAS DATA SETS; FUTURE GWAS AND GENE MAPPING APPROACHES; WEBSITES; REFERENCES; Section III -- Pancreatic Cancer Proteomics; Chapter 9 -- Proteomics in Pancreatic Cancer Translational Research; INTRODUCTION; OVERVIEW OF PROTEOMICS TECHNOLOGIES; PROTEOMICS STUDY OF PANCREATIC TISSUE; BLOOD BIOMARKER DISCOVERY; ANALYSIS OF PANCREATIC JUICE AND CYST FLUID; FUNCTIONAL AND HYPOTHESIS-DRIVEN PROTEOMIC STUDIES; POST-TRANSLATIONAL MODIFICATIONS; SUMMARY; ACKNOWLEDGMENT; REFERENCES -- Chapter 10 -- Proteomic Differences and Linkages between Chemoresistance and Metastasis of Pancreatic Cancer Using Knowledge-Based Pathway Analysis.
Access
Registration required for PDF access.
Format
e-Book
Location
Online
Less detail

Prostate cancer prevention

https://libcat.nshealth.ca/en/permalink/provcat33417
Jack Cuzick, Mangesh A. Thorat, editors. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide r…
Available Online
View e-Book
Other Authors
Cuzick, J
Thorat, Mangesh A
Responsibility
Jack Cuzick, Mangesh A. Thorat, editors
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (viii, 169 pages)
Series Vol.
v. 202
Series Title
Recent results in cancer research
ISBN
9783642451959 (electronic bk.)
9783642451942
Subjects (MeSH)
Prostatic Neoplasms - prevention & control
Anticarcinogenic Agents
Chemoprevention
Early Detection of Cancer
Risk Factors
Subjects (LCSH)
Prostate - Cancer - Prevention
Prostatic Neoplasms - prevention & control
Risk Assessment
Biological Markers
Life Style
Risk Factors
Diet
Chemoprevention
Oncology
Abstract
Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.
Contents
The biology and natural history of prostate cancer: a short introduction -- Germline genetic variants associated with prostate cancer and potential relevance to clinical practice -- Lifestyle and dietary factors in prostate cancer prevention -- Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition -- Screening for prostate cancer: current status of ERSPC and screening-related issues -- Update of the prostate, lung, colorectal, and ovarian cancer screening trial -- ERSPC, PLCO studies and critique of Cochrane review 2013 -- Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies -- Phase III prostate cancer chemoprevention trials -- Risk adapted chemoprevention for prostate cancer: an option? -- Aspirin and prostate cancer prevention -- Chemoprevention of prostate cancer by isoflavonoids -- Lycopene for the prevention and treatment of prostate disease -- Chemoprevention of prostate cancer with the polyamine -- Synthesis inhibitor difluoromethylornithine -- Prostate cancer prevention: agent development strategies -- Prognostic value of a cell cycle progression score for men with prostate cancer -- Distinguishing indolent from aggressive prostate cancer -- Management of low risk and low PSA prostate cancer: long term results from the prostate cancer intervention versus observation trial.
Format
e-Book
Location
Online
Less detail

Immunohistochemistry in Tumor Diagnostics

https://libcat.nshealth.ca/en/permalink/provcat42539
Muin S.A. Tuffaha, Hans Guski, Glen Kristiansen. --Cham: Springer , c2018.
Available Online
View e-Book
Location
Online
This book offers a comprehensive yet concise overview of immunoprofile of tumors and antibodies used in contemporary surgical pathology, and provides diagnostic algorithms for approaching tumor diagnostics. Immunohistochemistry has become the most important ancillary technique in diagnostic pathology in the last 20 years, and unlike most books on tumor diagnostics, this volume discusses in details immunohistochemical biomarkers, diagnostic approaches and their pitfalls, as well as the immunopro…
Available Online
View e-Book
Author
Tuffaha, Muin S.A
Other Authors
Guski, Hans
Kristiansen, Glen
Responsibility
Muin S.A. Tuffaha, Hans Guski, Glen Kristiansen
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xii, 264 p.) : 139 illus. in color
ISBN
9783319535777
9783319535760 (print ed.)
9783319535784 (print ed.)
9783319851884 (print ed.)
Subjects (MeSH)
Immunohistochemistry - methods
Neoplasms - diagnosis
Specialty
Clinical Laboratory Techniques
Medical Oncology
Abstract
This book offers a comprehensive yet concise overview of immunoprofile of tumors and antibodies used in contemporary surgical pathology, and provides diagnostic algorithms for approaching tumor diagnostics. Immunohistochemistry has become the most important ancillary technique in diagnostic pathology in the last 20 years, and unlike most books on tumor diagnostics, this volume discusses in details immunohistochemical biomarkers, diagnostic approaches and their pitfalls, as well as the immunoprofile of common tumors throughout all systems of human body. With numerous color figures and detailed flowcharts, it appeals to all pathologists be they young residents in training who want a brief introduction to this technique, or specialists in need of a reliable and comprehensive reference resource in tumors diagnostics.
Contents
Immunohistochemistry in tumor diagnosis -- Immunohistochemical markers for the diagnosis of epithelial tumors -- Markers and immunoprofile of upper respiratory tract and pulmonary tumors -- Markers and immunoprofile of thymic epithelial tumors -- Markers and immunoprofile of heart and pericardium tumors -- Markers and immunoprofile of tumors of the oral cavity and salivary gland tumors -- Markers and immunoprofile of tumors gastrointestinal tract -- Markers and immunoprofile of exocrine pancreatic tumors -- Markers and immunoprofile of hepatobiliary tumors -- Markers and immunoprofile of hepatobiliary tumors -- Markers and immunoprofile of breast tumors -- Markers and immunoprofile of tumors of female reproductive organs -- Markers and immunoprofile of renal and urinary tract tumors -- Markers and immunoprofile of male genital tract tumors -- Markers and immunoprofile of endocrine and neuroendocrine tumors -- Markers and immunoprofile of mesothelioma tumors of the peritoneum -- Markers and immunoprofile of lymphoid tissue neoplasms -- Markers and immunoprofile of myeloid neoplasm -- Markers and immunoprofile of Mastocytosis -- Markers and immunoprofile of histiocytic and dendritic cell tumors -- Markers and immunoprofile of skin tumors -- Markers and immunoprofile of melanocytic tumors -- Markers and immunoprofile of fibroblastic, myofibroblastic and fibrohistiocytic tumors -- Markers and immunoprofile of muscle tumors -- Markers and immunoprofile of vascular and perivascular tumors -- Markers and immunoprofile of adipocytic tumors -- Markers and immunoprofile of peripheral nerve- and nerve sheet tumors -- Markers and immunoprofile of the central nervous system tumors -- Markers and immunoprofile of Ewing's sarcoma / primitive neuroectodermal tumors (PNET) -- Markers and immunoprofile of extraskeletal osseous and cartilaginous tumors -- Markers and immunoprofile of miscellaneous tumors and tumors of uncertain differentiation -- Markers to assist the diagnosis of dysplasia and malignant transformation -- Recommendations for the utility of immunohistochemistry in tumor diagnosis.
Format
e-Book
Location
Online
Less detail

Improving the quality of cancer clinical trials : workshop summary

https://libcat.nshealth.ca/en/permalink/provcat27146
Institute of Medicine. --Washington, DC: National Academies Press , 2008.
Available Online
View e-Book
Access
Open access: download free PDF
Location
Online
Available Online
View e-Book
Corporate Author
Institute of Medicine
Place of Publication
Washington, DC
Publisher
National Academies Press
Date of Publication
2008
ISBN
9780309116688
Subjects (MeSH)
Clinical Trials as Topic
Neoplasms - drug therapy
Contents
New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy -- Concluding remarks.
Access
Open access: download free PDF
Format
e-Book
Location
Online
Less detail

176 records – page 1 of 9.